Lupin bags Health Canada approval for Tiotropium Bromide inhalation powder

Tiotropium Bromide Inhalation Powder is indicated for the long-term once-daily maintenance bronchodilator treatment of airflow obstruction in patients with COPD

Lupin announced that its Canada subsidiary, Lupin Pharma Canada, has received approval from Health Canada to market a generic version of Spiriva (tiotropium bromide inhalation powder) for the treatment of chronic obstructive pulmonary disease (COPD), in Canada.

Tiotropium Bromide Inhalation Powder is indicated for the long-term once-daily maintenance bronchodilator treatment of airflow obstruction in patients with COPD, including chronic bronchitis and/or emphysema. It is also used to relieve wheezing, shortness of breath, coughing and chest tightness in patients with COPD.

“This approval of the first generic for Tiotropium Bromide Inhalation Powder by Health Canada underscores our commitment to bringing affordable options of complex products for patients in Canada, particularly in the respiratory therapeutic area,” said, Dr Sofia Mumtaz, President – Legal, Canada, Australia, and Japan, Lupin.